WFS1_HUMAN,P7Q,0.050,-,-,-
WFS1_HUMAN,P16L,0.077,-,-,-
WFS1_HUMAN,V54G,0.216,-,-,-
WFS1_HUMAN,A57T,0.050,-,-,-
WFS1_HUMAN,Q66H,0.095,-,-,-
WFS1_HUMAN,M84V,0.031,-,-,-
WFS1_HUMAN,I86V,0.036,-,-,-
WFS1_HUMAN,V91I,0.031,-,-,-
WFS1_HUMAN,G115R,0.086,-,-,-
WFS1_HUMAN,T117M,0.059,-,-,-
WFS1_HUMAN,E120R,0.613,Loss of B-factor (Pr = 0.25 | P = 0.05), ELME000064|ELME000117|ELME000173|ELME000220|PS00006,-
WFS1_HUMAN,V131C,0.227,-,-,-
WFS1_HUMAN,V142L,0.467,-,-,-
WFS1_HUMAN,R161Q,0.038,-,-,-
WFS1_HUMAN,A214V,0.033,-,-,-
WFS1_HUMAN,M312R,0.679,Altered Transmembrane protein (Pr = 0.27 | P = 7.8e-04); Altered Ordered interface (Pr = 0.25 | P = 0.02), ELME000231|ELME000254,-
WFS1_HUMAN,T436A,0.141,-,-,-
WFS1_HUMAN,V498I,0.054,-,-,-
WFS1_HUMAN,V501I,0.103,-,-,-
WFS1_HUMAN,L506M,0.164,-,-,-
WFS1_HUMAN,V509I,0.089,-,-,-
WFS1_HUMAN,G576S,0.551,Altered Transmembrane protein (Pr = 0.29 | P = 2.5e-04), ELME000335|ELME000336,-
WFS1_HUMAN,R676H,0.497,-,-,-
WFS1_HUMAN,R685P,0.827,Loss of Helix (Pr = 0.32 | P = 2.5e-03); Altered Transmembrane protein (Pr = 0.30 | P = 1.7e-04); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Disulfide linkage at C690 (Pr = 0.18 | P = 0.03); Gain of Catalytic site at C690 (Pr = 0.15 | P = 0.02); Gain of GPI-anchor amidation at N682 (Pr = 0.01 | P = 0.03), ELME000052|ELME000202|ELME000336,-
WFS1_HUMAN,S308C,0.749,Altered Transmembrane protein (Pr = 0.32 | P = 7.3e-05), None,-
WFS1_HUMAN,P504R,0.850,Altered Ordered interface (Pr = 0.24 | P = 0.03); Gain of N-linked glycosylation at N500 (Pr = 0.07 | P = 0.02), ELME000070|ELME000106|ELME000146|ELME000155|ELME000336|PS00005,-
WFS1_HUMAN,G702D,0.927,Altered Transmembrane protein (Pr = 0.34 | P = 2.4e-05); Altered Ordered interface (Pr = 0.29 | P = 0.03); Altered DNA binding (Pr = 0.29 | P = 2.3e-03); Loss of Allosteric site at W700 (Pr = 0.27 | P = 8.9e-03); Gain of Relative solvent accessibility (Pr = 0.24 | P = 0.04); Altered Metal binding (Pr = 0.21 | P = 0.03), ELME000062|ELME000080|ELME000220|PS00005|PS00006,-
WFS1_HUMAN,Q584P,0.832,Altered Transmembrane protein (Pr = 0.29 | P = 2.3e-04), None,-
WFS1_HUMAN,V707F,0.840,Altered DNA binding (Pr = 0.29 | P = 3.5e-03); Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Ordered interface (Pr = 0.26 | P = 0.02); Altered Metal binding (Pr = 0.17 | P = 0.01), ELME000062|ELME000083|ELME000120|ELME000182,-
WFS1_HUMAN,P504L,0.801,Gain of Helix (Pr = 0.30 | P = 9.6e-03); Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Transmembrane protein (Pr = 0.09 | P = 0.05); Loss of N-linked glycosylation at N500 (Pr = 0.07 | P = 0.02), ELME000070|ELME000155|ELME000335|ELME000336,-
WFS1_HUMAN,P292S,0.789,Gain of Helix (Pr = 0.27 | P = 0.04); Altered Transmembrane protein (Pr = 0.21 | P = 4.9e-03), ELME000155,-
WFS1_HUMAN,N714I,0.921,Loss of Relative solvent accessibility (Pr = 0.34 | P = 2.8e-03); Altered Disordered interface (Pr = 0.32 | P = 0.02); Altered Ordered interface (Pr = 0.31 | P = 0.02); Altered Metal binding (Pr = 0.23 | P = 4.1e-03); Altered DNA binding (Pr = 0.22 | P = 0.02); Altered Transmembrane protein (Pr = 0.19 | P = 6.9e-03), ELME000085|ELME000147|ELME000220|ELME000233|ELME000321,-
WFS1_HUMAN,G834D,0.888,Altered Transmembrane protein (Pr = 0.39 | P = 9.7e-06), None,-
WFS1_HUMAN,G674V,0.878,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.28 | P = 4.3e-04); Loss of Disulfide linkage at C673 (Pr = 0.18 | P = 0.03), None,-
WFS1_HUMAN,V288M,0.135,-,-,-
WFS1_HUMAN,G437R,0.461,-,-,-
WFS1_HUMAN,Y669H,0.881,Altered Ordered interface (Pr = 0.37 | P = 1.7e-03); Altered Transmembrane protein (Pr = 0.24 | P = 1.5e-03); Loss of Disulfide linkage at C673 (Pr = 0.18 | P = 0.03), ELME000120,-
WFS1_HUMAN,M518V,0.835,Altered Transmembrane protein (Pr = 0.26 | P = 9.8e-04); Gain of Pyrrolidone carboxylic acid at Q520 (Pr = 0.06 | P = 0.02), None,-
WFS1_HUMAN,W700C,0.968,Loss of Allosteric site at W700 (Pr = 0.35 | P = 1.3e-03); Altered Ordered interface (Pr = 0.34 | P = 2.6e-03); Altered Transmembrane protein (Pr = 0.30 | P = 1.9e-04); Altered Metal binding (Pr = 0.28 | P = 0.02); Altered DNA binding (Pr = 0.22 | P = 0.02); Gain of Disulfide linkage at W700 (Pr = 0.16 | P = 0.03), ELME000062|ELME000080|ELME000137,-
WFS1_HUMAN,Y669C,0.905,Altered Ordered interface (Pr = 0.49 | P = 2.3e-04); Altered Transmembrane protein (Pr = 0.39 | P = 9.7e-06); Gain of Disulfide linkage at C673 (Pr = 0.23 | P = 0.01), ELME000120,-
WFS1_HUMAN,P346L,0.887,Loss of Strand (Pr = 0.31 | P = 1.3e-03); Altered Transmembrane protein (Pr = 0.30 | P = 1.9e-04); Gain of Helix (Pr = 0.30 | P = 6.8e-03); Altered Ordered interface (Pr = 0.24 | P = 0.03), None,-
WFS1_HUMAN,R708C,0.686,Altered DNA binding (Pr = 0.55 | P = 3.4e-05); Loss of Relative solvent accessibility (Pr = 0.34 | P = 3.1e-03); Altered Ordered interface (Pr = 0.33 | P = 8.4e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04); Altered Metal binding (Pr = 0.23 | P = 4.5e-03), ELME000062|ELME000083|ELME000120|ELME000182|ELME000220,-
WFS1_HUMAN,E158K,0.781,Altered Coiled coil (Pr = 0.37 | P = 0.01); Altered Disordered interface (Pr = 0.27 | P = 0.01); Gain of Acetylation at E158 (Pr = 0.23 | P = 0.02); Gain of SUMOylation at E158 (Pr = 0.20 | P = 0.03), ELME000064|PS00005|PS00006,-
WFS1_HUMAN,P320R,0.842,Gain of Helix (Pr = 0.28 | P = 0.03); Altered Transmembrane protein (Pr = 0.18 | P = 7.4e-03), ELME000052|ELME000053,-
WFS1_HUMAN,A559D,0.760,Altered Transmembrane protein (Pr = 0.36 | P = 1.9e-05); Altered Ordered interface (Pr = 0.25 | P = 0.03), ELME000062|ELME000313|ELME000336|PS00008,-
WFS1_HUMAN,G831A,0.759,Altered Transmembrane protein (Pr = 0.30 | P = 1.6e-04), ELME000220,-
WFS1_HUMAN,L303P,0.930,Altered Transmembrane protein (Pr = 0.31 | P = 1.2e-04); Altered Ordered interface (Pr = 0.31 | P = 4.1e-03); Altered Stability (Pr = 0.11 | P = 0.04), ELME000098|ELME000182,-
WFS1_HUMAN,I427S,0.814,Altered Transmembrane protein (Pr = 0.26 | P = 9.6e-04); Altered Stability (Pr = 0.10 | P = 0.04), ELME000007|ELME000053|ELME000063|ELME000136|ELME000159,-
WFS1_HUMAN,D797N,0.383,-,-,-
WFS1_HUMAN,V545M,0.413,-,-,-
WFS1_HUMAN,Y669S,0.923,Altered Ordered interface (Pr = 0.49 | P = 2.0e-04); Altered Transmembrane protein (Pr = 0.24 | P = 1.6e-03); Gain of Disulfide linkage at C673 (Pr = 0.19 | P = 0.02), ELME000053|ELME000085|ELME000120,-
WFS1_HUMAN,Y508C,0.705,Altered Ordered interface (Pr = 0.31 | P = 3.9e-03), ELME000020|ELME000083|ELME000120|ELME000182,-
WFS1_HUMAN,R859Q,0.331,-,-,-
WFS1_HUMAN,A684V,0.806,Loss of Helix (Pr = 0.29 | P = 9.9e-03); Altered Transmembrane protein (Pr = 0.26 | P = 7.2e-04), ELME000052|ELME000202|ELME000336,-
WFS1_HUMAN,E655K,0.855,Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Altered Ordered interface (Pr = 0.24 | P = 0.03); Loss of Sulfation at Y660 (Pr = 0.03 | P = 0.02), ELME000146,-
WFS1_HUMAN,N682D,0.597,Altered Transmembrane protein (Pr = 0.28 | P = 6.5e-04); Altered Ordered interface (Pr = 0.25 | P = 0.02), None,-
WFS1_HUMAN,R456H,0.622,Loss of Helix (Pr = 0.37 | P = 1.7e-04); Gain of Strand (Pr = 0.31 | P = 9.8e-04); Altered Transmembrane protein (Pr = 0.26 | P = 1.1e-03); Altered Ordered interface (Pr = 0.26 | P = 0.01), ELME000102|ELME000108|ELME000146|ELME000182|PS00005,-
WFS1_HUMAN,G786S,0.148,-,-,-
WFS1_HUMAN,V871M,0.369,-,-,-
WFS1_HUMAN,A671V,0.201,-,-,-
WFS1_HUMAN,V333F,0.695,Altered Transmembrane protein (Pr = 0.25 | P = 1.2e-03); Altered Ordered interface (Pr = 0.24 | P = 0.04); Loss of N-linked glycosylation at N335 (Pr = 0.08 | P = 0.02), ELME000328|ELME000336,-
WFS1_HUMAN,D866N,0.494,-,-,-
WFS1_HUMAN,P44T,0.089,-,-,-
WFS1_HUMAN,G51S,0.373,-,-,-
WFS1_HUMAN,G53S,0.053,-,-,-
WFS1_HUMAN,R71G,0.147,-,-,-
WFS1_HUMAN,A114R,0.499,-,-,-
WFS1_HUMAN,E119K,0.240,-,-,-
WFS1_HUMAN,L130P,0.898,Altered Stability (Pr = 0.12 | P = 0.03), ELME000155,-
WFS1_HUMAN,A141G,0.767,Altered Disordered interface (Pr = 0.27 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.03); Altered Coiled coil (Pr = 0.26 | P = 0.02); Gain of Acetylation at K143 (Pr = 0.20 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q136 (Pr = 0.20 | P = 1.9e-03); Altered Stability (Pr = 0.17 | P = 0.02), ELME000149|ELME000233,-
WFS1_HUMAN,L144T,0.696,Altered Coiled coil (Pr = 0.27 | P = 0.01); Altered Disordered interface (Pr = 0.25 | P = 0.01); Gain of Proteolytic cleavage at R147 (Pr = 0.11 | P = 0.04); Gain of Disulfide linkage at C148 (Pr = 0.10 | P = 0.05); Altered Stability (Pr = 0.10 | P = 0.04), ELME000149|ELME000233|ELME000337|PS00005,-
WFS1_HUMAN,R147Q,0.335,-,-,-
WFS1_HUMAN,A150R,0.571,Altered Disordered interface (Pr = 0.59 | P = 5.6e-04); Gain of Intrinsic disorder (Pr = 0.33 | P = 0.03); Altered Coiled coil (Pr = 0.25 | P = 0.02); Loss of Proteolytic cleavage at R147 (Pr = 0.12 | P = 0.04), ELME000101,-
WFS1_HUMAN,H210Q,0.062,-,-,-
WFS1_HUMAN,I250V,0.103,-,-,-
WFS1_HUMAN,M306V,0.055,-,-,-
WFS1_HUMAN,A406V,0.140,-,-,-
WFS1_HUMAN,F413V,0.260,-,-,-
WFS1_HUMAN,I421L,0.141,-,-,-
WFS1_HUMAN,N477D,0.046,-,-,-
WFS1_HUMAN,L514V,0.469,-,-,-
WFS1_HUMAN,A602V,0.075,-,-,-
WFS1_HUMAN,V606M,0.151,-,-,-
WFS1_HUMAN,V624L,0.101,-,-,-
WFS1_HUMAN,S743R,0.154,-,-,-
WFS1_HUMAN,D788E,0.101,-,-,-
WFS1_HUMAN,T857A,0.033,-,-,-
WFS1_HUMAN,R832G,0.707,Altered Transmembrane protein (Pr = 0.28 | P = 4.6e-04); Altered Stability (Pr = 0.10 | P = 0.04), PS00008,-
WFS1_HUMAN,A844T,0.636,Altered Transmembrane protein (Pr = 0.27 | P = 8.4e-04); Altered Metal binding (Pr = 0.25 | P = 0.03), None,-
WFS1_HUMAN,P292T,0.815,Gain of Helix (Pr = 0.27 | P = 0.03); Altered Transmembrane protein (Pr = 0.19 | P = 6.6e-03), ELME000155|ELME000182,-
WFS1_HUMAN,W314R,0.677,Altered Ordered interface (Pr = 0.34 | P = 2.9e-03); Altered Transmembrane protein (Pr = 0.28 | P = 5.6e-04); Gain of Helix (Pr = 0.27 | P = 0.03), ELME000053|ELME000062|ELME000173|ELME000254,-
WFS1_HUMAN,T337I,0.681,Altered Transmembrane protein (Pr = 0.35 | P = 3.4e-05); Loss of N-linked glycosylation at N335 (Pr = 0.08 | P = 0.01), ELME000063|ELME000070|ELME000148|ELME000333|PS00001,-
WFS1_HUMAN,N188S,0.343,-,-,-
WFS1_HUMAN,G674E,0.815,Altered Metal binding (Pr = 0.39 | P = 9.1e-03); Altered Transmembrane protein (Pr = 0.33 | P = 4.9e-05); Altered Ordered interface (Pr = 0.33 | P = 7.4e-03); Gain of Disulfide linkage at C673 (Pr = 0.20 | P = 0.02), None,-
WFS1_HUMAN,F350I,0.819,Altered Ordered interface (Pr = 0.25 | P = 0.02); Altered Transmembrane protein (Pr = 0.11 | P = 0.04), ELME000328|ELME000333|ELME000336,-
WFS1_HUMAN,S443I,0.730,Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000052|ELME000063|ELME000336,-
WFS1_HUMAN,N682S,0.465,-,-,-
WFS1_HUMAN,I845N,0.900,Altered Transmembrane protein (Pr = 0.43 | P = 0.0e+00); Altered Metal binding (Pr = 0.30 | P = 0.02), ELME000079,-
WFS1_HUMAN,S356P,0.798,Loss of Helix (Pr = 0.29 | P = 0.02); Altered Ordered interface (Pr = 0.24 | P = 0.03); Altered Transmembrane protein (Pr = 0.02 | P = 3.4e-03), ELME000063,-
WFS1_HUMAN,L506R,0.726,Loss of Helix (Pr = 0.28 | P = 0.03); Altered Ordered interface (Pr = 0.24 | P = 0.04), ELME000020,-
